Natera Performance degli utili passati
Criteri Il passato verificati 0/6
Natera ha registrato una crescita degli utili a un tasso medio annuo di 14.1%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 33.8%. I ricavi sono stati in crescita a un tasso medio annuo di 32.4%.
Informazioni chiave
14.06%
Tasso di crescita degli utili
22.33%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.04% |
| Tasso di crescita dei ricavi | 32.42% |
| Rendimento del capitale proprio | -12.76% |
| Margine netto | -9.05% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Articolo di analisi • May 13
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...
Aggiornamento della narrazione • May 05
NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory
Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
Aggiornamento della narrazione • Apr 20
NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook
Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.
Aggiornamento della narrazione • Apr 05
NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook
Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.Aggiornamento della narrazione • Mar 22
NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook
The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.Seeking Alpha • Mar 17
Natera Looks Compelling As Oncology Testing Momentum Keeps Building
Summary NTRA’s oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA’s 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio. Their Foresight acquisition also strengthens NTRA’s MRD moat through PhasED-Seq technology, better testing sensitivity, and taps into lymphoma screening. I reckon NTRA’s valuation multiples are expensive. However, I think their current growth rate with Signatera justifies its price tag, which is why I lean bullish. Read the full article on Seeking AlphaAggiornamento della narrazione • Mar 07
NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside
The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.Aggiornamento della narrazione • Feb 21
NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory
Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.Aggiornamento della narrazione • Feb 07
NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook
Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.Aggiornamento della narrazione • Jan 24
NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory
Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.Aggiornamento della narrazione • Jan 09
NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory
Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.Aggiornamento della narrazione • Dec 26
NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory
The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.Aggiornamento della narrazione • Dec 12
NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns
Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.Aggiornamento della narrazione • Nov 27
NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook
Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.Aggiornamento della narrazione • Nov 11
NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance
Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.Aggiornamento della narrazione • Oct 27
Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets
Analysts raised their fair value estimate for Natera to $202.50 from $193.80. They cited momentum from recent clinical developments, positive trial updates, and ongoing strength in the company’s diagnostic and oncology business lines.Aggiornamento della narrazione • Sep 28
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts lowered Natera’s price target modestly to $193.80 as continued optimism around its liquid biopsy leadership and growth opportunities was tempered by renewed concerns about elevated valuation and margin outlook. Analyst Commentary Bullish analysts note Natera's leadership in liquid biopsy testing and large addressable markets in prenatal, minimal residual disease, and potential cancer screening, supporting long-term double-digit revenue growth.Aggiornamento della narrazione • Sep 04
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.Articolo di analisi • Aug 31
Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
Natera, Inc. ( NASDAQ:NTRA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Nuova narrazione • May 11
Signatera, Prospera And Renasight Will Transform Diagnostics
Strong revenue growth driven by increased diagnostic volumes and strategic partnerships positively impacts Natera's earnings and future revenue potential.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Natera guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 2,501 | -226 | 1,231 | 706 |
| 31 Dec 25 | 2,306 | -208 | 1,177 | 624 |
| 30 Sep 25 | 2,117 | -309 | 1,121 | 578 |
| 30 Jun 25 | 1,964 | -253 | 1,026 | 502 |
| 31 Mar 25 | 1,831 | -190 | 914 | 445 |
| 31 Dec 24 | 1,697 | -190 | 841 | 404 |
| 30 Sep 24 | 1,532 | -215 | 768 | 358 |
| 30 Jun 24 | 1,361 | -292 | 708 | 338 |
| 31 Mar 24 | 1,209 | -365 | 663 | 327 |
| 31 Dec 23 | 1,083 | -435 | 618 | 321 |
| 30 Sep 23 | 989 | -499 | 601 | 326 |
| 30 Jun 23 | 931 | -512 | 594 | 314 |
| 31 Mar 23 | 868 | -546 | 591 | 318 |
| 31 Dec 22 | 820 | -548 | 589 | 316 |
| 30 Sep 22 | 776 | -546 | 592 | 300 |
| 30 Jun 22 | 723 | -576 | 572 | 333 |
| 31 Mar 22 | 667 | -546 | 550 | 304 |
| 31 Dec 21 | 625 | -472 | 511 | 264 |
| 30 Sep 21 | 565 | -408 | 453 | 231 |
| 30 Jun 21 | 505 | -315 | 402 | 157 |
| 31 Mar 21 | 449 | -258 | 346 | 122 |
| 31 Dec 20 | 391 | -230 | 304 | 100 |
| 30 Sep 20 | 362 | -189 | 272 | 77 |
| 30 Jun 20 | 342 | -153 | 251 | 65 |
| 31 Mar 20 | 330 | -126 | 226 | 58 |
| 31 Dec 19 | 302 | -125 | 204 | 51 |
| 30 Sep 19 | 286 | -121 | 189 | 49 |
| 30 Jun 19 | 273 | -128 | 170 | 49 |
| 31 Mar 19 | 262 | -129 | 161 | 48 |
| 31 Dec 18 | 258 | -128 | 155 | 51 |
| 30 Sep 18 | 243 | -144 | 163 | 50 |
| 30 Jun 18 | 233 | -142 | 159 | 50 |
| 31 Mar 18 | 223 | -137 | 156 | 50 |
| 31 Dec 17 | 210 | -138 | 155 | 50 |
| 30 Sep 17 | 207 | -128 | 144 | 49 |
| 30 Jun 17 | 205 | -126 | 144 | 47 |
| 31 Mar 17 | 205 | -121 | 143 | 46 |
| 31 Dec 16 | 213 | -100 | 136 | 42 |
| 30 Sep 16 | 221 | -81 | 129 | 38 |
| 30 Jun 16 | 212 | -72 | 122 | 34 |
| 31 Mar 16 | 205 | -69 | 117 | 31 |
| 31 Dec 15 | 190 | -70 | 110 | 28 |
| 30 Sep 15 | 187 | -46 | 98 | 24 |
| 30 Jun 15 | 189 | -28 | 86 | 21 |
Guadagni di qualità: NTRA al momento non è redditizia.
Margine di profitto in crescita: NTRA al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: NTRA non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 14.1% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di NTRA nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: NTRA non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 43% ).
Rendimento del capitale proprio
ROE elevato: NTRA ha un Return on Equity negativo ( -12.76% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/20 09:13 |
| Prezzo dell'azione a fine giornata | 2026/05/20 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Natera, Inc. è coperta da 30 analisti. 18 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Raymond Myers | Benchmark Company |